Anti- @entity3900 Receptor Antibody Titer Predicts Post-Rituximab Outcome of XXXX .

@entity1 @entity644 @entity8 @entity8167 @entity3900 @entity8164 @entity1985
UNASSIGNED: Rituximab induces @entity1985 ( @entity1985 ) remission in two-thirds of @entity1 with primary @entity8 ( @entity8 ), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti- @entity3900 receptor (anti- @entity8164 ) autoantibodies and genetic polymorphisms predisposing to antibody production we serially monitored 24-hour @entity644 and antibody titer in @entity1 with primary @entity8 and long-lasting @entity1985 consenting to rituximab (375 mg/m(2)) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0-145.4) months, 84 of 132 rituximab-treated @entity1 achieved complete or partial @entity1985 remission (primary end point), and 25 relapsed after remission. Outcomes of @entity1 with or without detectable anti- @entity8164 antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti- @entity8164 antibody titer at baseline (P=0.001) and full antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P<0.001) strongly predicted remission. All 25 complete remissions were preceded by complete anti- @entity8164 antibody depletion. On average, 50% anti- @entity8164 titer reduction preceded equivalent @entity644 reduction by 10 months. Re-emergence of circulating antibodies predicted disease relapse (HR, 6.54; 95% CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 95% CI, 2.37 to 18.53; P<0.001). Eighteen @entity1 achieved persistent antibody depletion and complete remission and never relapsed. Outcome was independent of @entity8164 and @entity8167 polymorphisms and of previous immunosuppressive treatment. Therefore, assessing circulating anti- @entity8164 autoantibodies and @entity644 may help in monitoring disease activity and guiding personalized rituximab therapy in @entity1985 @entity1 with primary @entity8 .
